A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)

Фаза 2 Завершено NCT05258071

Заболевание	Parkinson Disease
Фаза	Фаза 2
Спонсор	Integrative Research Laboratories AB
Статус	Завершено
Участники	104 участн.
Вмешательство	Pirepemat
Дата начала	15.06.2022
Дата завершения	4.12.2024
Публикация результатов	9.07.2026

Кратко

This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.

Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment.

Baseline to end of full dose treatment (up to Day 84). · % of baseline fall rate

Pirepemat 300 mg	76.9 ± 72.05 % of baseline fall rate
Pirepemat 600 mg	64.5 ± 49.18 % of baseline fall rate
Placebo	68.9 ± 90.22 % of baseline fall rate

p-value	0.5753
Median ratio	0.973 (95% CI 0.706–1.274)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given P — Merck Sharp & Dohme LLC
Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers — Rutgers, The State University of New Jersey
Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation — Duke University
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemot — Merck Sharp & Dohme LLC
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advan — Merck Sharp & Dohme LLC
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With E — Hoffmann-La Roche

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский